Clinical Trials
186 trialsRegorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
GBM AGILE
Global Coalition for Adaptive Research
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
TAPUR
American Society of Clinical Oncology
REVIVE
Asan Medical Center
REGINA
Jules Bordet Institute
PARERE
Gruppo Oncologico del Nord-Ovest
MIRAGE
Istituto Oncologico Veneto IRCCS
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
West China Hospital
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
MegaMOST
Centre Leon Berard
RELEVANT-HCC
Asan Medical Center
RECOMEND
Asan Medical Center
Regbone
Institute of Mother and Child, Warsaw, Poland
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
REBECCA
Centre Oscar Lambret
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
REPLACE
Translational Research in Oncology
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
DREAM
First Affiliated Hospital, Sun Yat-Sen University
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
M.D. Anderson Cancer Center
REGOSTA
Centre Leon Berard
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Jinling Hospital, China
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
REGOMA-2
Istituto Oncologico Veneto IRCCS
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
REGOBONE
UNICANCER
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United